ImmunoPrecise Antibodies Ltd.
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. ImmunoPrecise Antibodies Ltd.'s past years’ income statements indicate that its last revenue has increased compared to the previous period by 19% to $24,518,000. Profit margin reached -111%. Total operating expenses were $12,053,000.

Profit Margin

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA): Profit margin
2013 0 69.44K
2016 1.89M 151.03K 7.97%
2017 2.63M -5.38M -204.67%
2018 5.44M -5.17M -95.03%
2019 10.92M -7.61M -69.72%
2020 14.05M -4.94M -35.19%
2021 17.91M -7.34M -40.98%
2022 19.36M -16.70M -86.29%
2023 20.66M -26.56M -128.53%
2024 24.51M -27.17M -110.85%

IPA Income Statement (2014 – 2024)

2024 2023 2021 2020 2020 2018 2017 2017 2015 2014
Revenue
Revenue
24.51M20.66M19.36M17.91M14.05M10.92M5.44M2.63M1.89M0
Cost of revenue
12.46M9.10M8.38M6.37M6.02M5.63M2.99M1.20M298.31K0
Gross profit
12.05M11.56M10.98M11.53M8.03M5.29M2.45M1.42M1.59M0
Operating exp.
Research and development
4.04M12.28M6.69M1.97M446.28K485.84K509.24K660.40K302.76K0
Selling and marketing
3.54M3.60M740K691K377.72K819.25K134.68K119.19K20.83K0
Total operating expenses
12.05M39.78M27.15M15.71M12.08M11.51M7.21M7.84M1.66M97.43K
Operating income
-13.76M-26.09M-15.78M-6.65M-4.09M-6.22M-4.92M-1.38M242.64K-97.55K
Other income (expenses), net
-14.94M-2.14M462K-1.23M-1.46M-99.21K-323.18K-4.07M17.04K167K
Income before tax
-28.70M-27.75M-15.84M-5.99M-5.29M-7.61M-5.06M-5.46M242.64K69.44K
Income tax expense
-1.52M-1.19M861K1.34M-345.72K4.78K109.71K-82.37K91.61K120
Net income
-27.17M-26.56M-16.70M-7.34M-4.94M-7.61M-5.17M-5.38M151.03K69.44K
Earnings per share
Basic EPS
-1.06-1.07-0.85-0.45-0.36-0.61-0.57-1.360.10.11
Diluted EPS
-1.06-1.07-0.85-0.45-0.36-0.61-0.57-1.360.10.11
Data sourceData source